This inventor holds 35 USPTO granted patents and 7 published patent applications, plus 7 CIPO patents and 8 EPO patents, primarily in Antibody Therapeutics. Top assignees: Celldex Therapeutics Limited, Dana-Farber-Cancer Institute Inc., Emory University. Active years: 2011-2024.
Location History:
- Cambs, GB (2016 - 2017)
- Cambridgeshire, GB (2011 - 2022)
- Babraham, GB (2015 - 2024)
Company Filing History:
5 out of 45 
5 out of 1,264 
5 out of 1,022 
Years Active: 2011-2024
Areas of Expertise:
Title: **Timothy David Jones: Innovator in Antibody Therapeutics**
Introduction
Timothy David Jones is a distinguished inventor based in Babraham, GB, known for his groundbreaking work in the field of antibody therapeutics. With a remarkable portfolio of 35 patents, his contributions have significantly advanced the understanding and treatment of various diseases, particularly those related to cancer and KIT-associated disorders.
Latest Patents
His latest innovations include two significant patents:
1. **Anti-KIT Antibodies and Uses Thereof**
This patent presents antibodies that specifically bind to the human KIT antigen, particularly targeting the fourth and fifth extracellular Ig-like domains. These antibodies play a crucial role in inhibiting KIT activity, which is vital for treating or managing disorders associated with this receptor. The patent also outlines methods for diagnosing KIT-associated diseases using these antibodies, along with associated pharmaceutical compositions.
2. **Anti-MET Antibodies and Methods of Use Thereof**
This patent involves antibodies designed to bind to MET, a receptor tyrosine kinase that is important in cancer pathways. The innovation includes methods to modulate the expression of MET and ways to manage, treat, or prevent cancer through the use of monoclonal antibodies targeting the Sema/PSI domain of human MET. The patent also details the development of kits comprising these antibodies for therapeutic use.
Career Highlights
Timothy's career includes significant roles at esteemed institutions, such as Emory University and the Dana-Farber Cancer Institute. His research has focused on therapeutic applications of monoclonal antibodies, establishing him as a leader in the biotechnology field.
Collaborations
Throughout his career, Timothy has collaborated with esteemed professionals, including Francis Joseph Carr and Francis J Carr. These partnerships have facilitated advancements in research and the development of innovative therapeutics.
Conclusion
Timothy David Jones exemplifies the spirit of innovation in biotechnology. His extensive patent portfolio demonstrates his commitment to improving patient outcomes through targeted therapies, particularly in the realm of cancer treatment. As he continues to work at the intersection of science and medicine, his contributions are likely to pave the way for future breakthroughs in antibody therapeutics.